Here are the S-3 shelf registrations from Medicus Pharma Ltd. (MDCX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow MDCX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDCX filings page.
Medicus Pharma Ltd. has filed a resale registration covering up to 4,020,000 common shares issuable on exercise of existing Private Warrants held by Armistice Capital Master Fund Ltd. Each warrant is immediately exercisable for one common share at an exercise price of $2.00 and expires on June 5, 2031.
The company is not selling shares in this registration and will not receive proceeds from resales by the selling shareholder, though it may receive up to $8,040,000 if the warrants are exercised for cash. Common shares trade on Nasdaq under “MDCX,” and the company qualifies as an emerging growth and smaller reporting company.